ストックスクリーナーアプリを入手
1.77
1.39%
-0.025
アフターアワーズ：
1.75
-0.02
-1.13%
前日終値:
$1.795
開ける：
$1.78
24時間の取引高:
122.20K
Relative Volume:
0.47
時価総額：
$52.32M
収益：
$210.70K
当期純損益:
$-21.37M
株価収益率:
-1.6091
EPS:
-1.1
ネットキャッシュフロー:
$-21.10M
1週間 パフォーマンス:
-1.67%
1か月 パフォーマンス:
-5.85%
6か月 パフォーマンス:
-4.84%
1年 パフォーマンス:
-29.48%
1日の値動き範囲:
$1.76
$1.825
1週間の範囲:
$1.74
$1.85
52週間の値動き範囲:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
GANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.77 | 53.20M | 210.70K | -21.37M | -21.10M | -1.10 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-08-14 | 再開されました | Oppenheimer | Outperform |
| 2021-04-12 | 開始されました | BTIG Research | Buy |
| 2021-04-12 | 開始されました | Oppenheimer | Outperform |
Gain Therapeutics Inc (GANX) 最新ニュース
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - Yahoo Finance
Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal - Nasdaq
Gain Therapeutics' Chief Medical Officer Set to Reveal Latest GBA1 Therapeutic Developments in Montreal - Stock Titan
Gain Therapeutics Files $100 Million Mixed Shelf - marketscreener.com
Gain Therapeutics (GANX) Pursues $100 Million Securities Offerin - GuruFocus
Gain Therapeutics (GANX) Pursues $100 Million Securities Offering | GANX Stock News - GuruFocus
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings - Benzinga
CytomX Therapeutics Inc’s (CTMX) 4.41% Gain Is A Reason To Reconsider. - Stocksregister
HC Wainwright Brokers Increase Earnings Estimates for GANX - Defense World
Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Buy” by Analysts - Defense World
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - Defense World
Gain Therapeutics (GANX) Maintains 'Buy' Rating with $8 Price Ta - GuruFocus
Roth Capital Predicts Reduced Earnings for Gain Therapeutics - Defense World
Gain Therapeutics Reports Q1 2025 Financial Results - TipRanks
Gain Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gain (GANX) Advances Parkinson's Treatment in Phase 1b Trials | - GuruFocus
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - The Manila Times
Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development - Nasdaq
Gain Therapeutics' Parkinson's Drug Shows Promise: Key Biomarker Data Coming Mid-2025 - Stock Titan
Zevra Therapeutics Q1 Net Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Gain Therapeutics (GANX) Showcases Promising Parkinson's Treatme - GuruFocus
Gain Therapeutics, Inc. Presents New Evidence for GT-02287 as Potential Disease-Modifying Therapy for Parkinson’s Disease at IAPRD 30th World Congress - Nasdaq
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - TradingView
Gain Therapeutics (GANX) Expected to Announce Earnings on Tuesday - Defense World
Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Gaining Ground: Verve Therapeutics Inc (VERV) Closes Lower at 5.95, Down -11.33 - DWinneX
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Gain Therapeutics Inc (GANX) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Market Watch: Soleno Therapeutics Inc (SLNO)’s Noteworthy Gain, Closing at 75.02 - DWinneX
Gain Therapeutics Inc [GANX] Records 50-Day SMA of $1.9700 - knoxdaily.com
Gaining Ground: SpringWorks Therapeutics Inc (SWTX) Closes Higher at 46.30, Up 0.13 - DWinneX
Gain Therapeutics Inc (GANX) Stock: Navigating Drops and Gains - investchronicle.com
Market Watch: ITeos Therapeutics Inc (ITOS)’s Noteworthy Gain, Closing at 7.25 - DWinneX
Gain Therapeutics to Participate at The Citizens Life Sciences Conference - Eagle-Tribune
Gain Therapeutics Inc (GANX) deserves deeper analysis - uspostnews.com
Gain Therapeutics CEO to Showcase Next-Gen Allosteric Therapies at Major Healthcare Conference - Stock Titan
Gain Therapeutics Announces Oral Poster Presentation - marketscreener.com
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics, Inc. Announces Oral Poster Presentation of GT-02287 for Parkinson's Disease at IAPRD 30th World Congress - Nasdaq
Breakthrough: Novel Drug GT-02287 Demonstrates Neuroprotective Effects in Parkinson's Disease - Stock Titan
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain - Yahoo Finance
Gaining Ground: Structure Therapeutics Inc ADR (GPCR) Closes Lower at 23.62, Down -0.51 - DWinneX
Gain Therapeutics Inc (GANX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):